Regeneron to acquire 23andMe's assets, including its genetic data, in a bankruptcy deal, aiming to enhance drug development while prioritizing privacy and ethics.
Regeneron to acquire 23andMe's assets, including its genetic data, in a bankruptcy deal, aiming to enhance drug development while prioritizing privacy and ethics.